Lastly, we investigate the involved upstream RNA-binding proteins (RBPs) and identify PTBP1 as a promising therapeutic target to dampen the malignant AS signature while promoting neuronal-like differentiation in glioma cells. This evidence concerns the gene PTBP1 and glioma.